Member Info for Laura2022

Eg

Troutisout1

Posted in: PYC

Posts: 1,155

Price: 0.44

No Opinion

RE: Bidding10 Jun 2025 14:55

Nope, thought they delayed it, but looks like they have put it through a minute after the trade was executed?

Troutisout1

Posted in: PYC

Posts: 1,155

Price: 0.44

No Opinion

RE: Bidding10 Jun 2025 14:49

Just bought a tad over 3m in two tranches the second will be printed in an hour.

Trout

Good morning , first posts since you bought a few million mid June

Do we take it you sold....again ??

Have you added recently OSD,?

I suspect a mid morning up lift and once this news becomes more well known to wider investment community this will sink in

Stockraiser

Many A.I stocks are valued at x100 their annual revenues on AIM

PYC on that basis should be 20p+

GE HealthCare Technologies Inc. (NasdaqGS:GEHC) completed the acquisition of MIM Software Inc. for approximately $290 million on April 1, 2024. GEHC acquired MIM for approximately $258 million, net of cash acquired, and up to $35 million in cash upon the completion of certain milestones and service requirements.31 Mar 2024

Investors in PYC have always believed the dosing tool...which , dont forget , can be rolled to otjer companies, should be worth $$mlns

Nt to buy 0.5p

Momentum is increasing rapidly

10th July : integration of PYC platform into global personalosed medical provoder DoseMeRx

1st July - new contract

16th June x 2 biostatistics contracts (first ones from new division)

29th May RNSPhysiomics Awarded Contract Extension

9th May RNSContract Award with New UK Client

17th Apr Physiomics Awarded New Contract

16th Apr RNS-R Publication of Peer Reviewed Article

15th Apr new contract

17th Mar RNS Contract Award with new client

PYC £1 3mln market value looks to be crazy when you look at the potential of this dosing tool

One personalised dosing tool was bought by GE for $50mln 12mtjs ago

Dr Peter Sargent, CEO of Physiomics, commented:

"We are very excited to announce our expanded partnership with DoseMe and the implementation of our Personalised Dosing Software onto their newly launched DoseMeRx platform. This not only marks a positive step towards the eventual commercialisation of our current Personalised Dosing Software, but also our ambition to apply our extensive modelling expertise into the development of new dosing software, either in oncology or beyond."

Dr Sharmeen Roy, PharmD, BCPS, Chief Strategy and Science Office of DoseMe, Commented:

"Embedding Physiomics' oncology models into DoseMeRx aligns with our focus on advancing transitional precision dosing. This collaboration expands our oncology strategy and supports the broader clinical adoption of model-informed approaches."

From KingHomerJ

The Trial is on GCFS…..

The software was initially developed to support clinicians make cancer chemotherapy (docetaxel) dosing decisions, helping to optimise dosing for individual patients to improve patient outcomes. However, as a result of the PARTNER study (completed in January 2023), a second utility was observed, in that the software could be used to support the dosing of an expensive biological drug GCSF. This drug is routinely used in many countries to counteract the toxic effect chemotherapy has on patient's white blood cells - a condition known as neutropenia.

This covers ALL TYPES OF CANCER

GCSF is most expensive treatment on earth

The market is anticipated to reach between $9.17 billion and $12.4 billion by 2032

Physiomics Implements Personalised Dosing Software onto the DoseMeRx Platform and expands partnership with DoseMe

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the implementation of the Company's personalised dosing software onto the DoseMeRx platform and the expansion of its partnership with DoseMe to support the development of new dosing solutions.

Following several iterations of software deployment, evaluation and debugging, the Company has successfully implemented its dosing software onto DoseMe's latest platform. This now allows the tool to be made available to clinicians and health care providers on a research-only basis allowing for important human factor evaluation and additional validation data to be generated.

In addition, Physiomics and DoseMe have agreed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software.

Delayed 1.7mln buy at 0.47

Nearly 40% up but I'm holding for IPO

1.5mln +

Burt

If its Avocet123...again !!..just look at the stuff hes been investing/pushing last 12mths

Including ROCK

Dr. Peter Sargent , CEO of Physiomics, commented: “The last six months have been a transformative period for Physiomics. As we expand our capabilities in biometrics and continue to enhance our modelling and simulation services, we’re in a strong position to help our clients accelerate drug development. Our focus remains on providing innovative, data-driven solutions that empower smarter decisions and improve patient outcomes.”

Maybe due to the TR1 seller rather than results?

Tempting

2p+ is achievable this week